APO Research
Talk to an analyst

APO RESEARCH · REPORT

C-X-C Chemokine Receptor Type 2

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global C-X-C Chemokine Receptor Type 2 Market Outlook and Growth Opportunities 2026

19 December 2025195 pages

Choose your research edition.

Industry ResearchC-X-C Chemokine Receptor Type 2 Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal C-X-C Chemokine Receptor Type 2 Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal C-X-C Chemokine Receptor Type 2 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal C-X-C Chemokine Receptor Type 2 Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal C-X-C Chemokine Receptor Type 2 Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global C-X-C Chemokine Receptor Type 2 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for C-X-C Chemokine Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for C-X-C Chemokine Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for C-X-C Chemokine Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the C-X-C Chemokine Receptor Type 2 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the C-X-C Chemokine Receptor Type 2 market include ChemoCentryx Inc, Dompe Farmaceutici SpA, Syntrix Biosystems Inc, AstraZeneca Plc, GlaxoSmithKline Plc and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global C-X-C Chemokine Receptor Type 2 market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of C-X-C Chemokine Receptor Type 2 and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents C-X-C Chemokine Receptor Type 2 revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global C-X-C Chemokine Receptor Type 2 market.

C-X-C Chemokine Receptor Type 2 Segment by Company

ChemoCentryx Inc

Dompe Farmaceutici SpA

Syntrix Biosystems Inc

AstraZeneca Plc

GlaxoSmithKline Plc

Novartis AG

C-X-C Chemokine Receptor Type 2 Segment by Type

SX-517

PAC-G31P

DF-2755A

AZD-5069

Others

C-X-C Chemokine Receptor Type 2 Segment by Application

Prostate Cancer

Cornary Artery Disease

Liver Transplant Rejection

Pulmonary Inflammation

Others

C-X-C Chemokine Receptor Type 2 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global C-X-C Chemokine Receptor Type 2 status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the C-X-C Chemokine Receptor Type 2 key companies, revenue, market share, and recent developments.

3. To split the C-X-C Chemokine Receptor Type 2 breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions C-X-C Chemokine Receptor Type 2 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify C-X-C Chemokine Receptor Type 2 significant trends, drivers, influence factors in global and regions.

6. To analyze C-X-C Chemokine Receptor Type 2 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global C-X-C Chemokine Receptor Type 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of C-X-C Chemokine Receptor Type 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of C-X-C Chemokine Receptor Type 2.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global C-X-C Chemokine Receptor Type 2 industry.

Chapter 3: Detailed analysis of C-X-C Chemokine Receptor Type 2 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of C-X-C Chemokine Receptor Type 2 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of C-X-C Chemokine Receptor Type 2 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. C-X-C Chemokine Receptor Type 2 Industry Trends Table 2. C-X-C Chemokine Receptor Type 2 Industry Drivers Table 3. C-X-C Chemokine Receptor Type 2 Industry Opportunities and Challenges Table 4. C-X-C Chemokine Receptor Type 2 Industry Restraints Table 5. Global C-X-C Chemokine Receptor Type 2 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global C-X-C Chemokine Receptor Type 2 Revenue Share by Company (2021-2026) Table 7. Global C-X-C Chemokine Receptor Type 2 Company Ranking, (2024-2026) & (US$ Million) Table 8. Global C-X-C Chemokine Receptor Type 2 Key Company Manufacturing Base & Headquarters Table 9. Global C-X-C Chemokine Receptor Type 2 Company, Product Type & Application Table 10. Global C-X-C Chemokine Receptor Type 2 Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global C-X-C Chemokine Receptor Type 2 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of SX-517 Table 15. Significant Companies of PAC-G31P Table 16. Significant Companies of DF-2755A Table 17. Significant Companies of AZD-5069 Table 18. Significant Companies of Others Table 19. Global C-X-C Chemokine Receptor Type 2 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global C-X-C Chemokine Receptor Type 2 Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global C-X-C Chemokine Receptor Type 2 Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global C-X-C Chemokine Receptor Type 2 Sales Value Share by Type (2021-2026) Table 23. Global C-X-C Chemokine Receptor Type 2 Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Prostate Cancer Table 25. Significant Companies of Cornary Artery Disease Table 26. Significant Companies of Liver Transplant Rejection Table 27. Significant Companies of Pulmonary Inflammation Table 28. Significant Companies of Others Table 29. Global C-X-C Chemokine Receptor Type 2 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global C-X-C Chemokine Receptor Type 2 Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global C-X-C Chemokine Receptor Type 2 Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global C-X-C Chemokine Receptor Type 2 Sales Value Share by Application (2021-2026) Table 33. Global C-X-C Chemokine Receptor Type 2 Sales Value Share by Application (2027-2032) Table 34. Global C-X-C Chemokine Receptor Type 2 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global C-X-C Chemokine Receptor Type 2 Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global C-X-C Chemokine Receptor Type 2 Sales Value Share by Region (2021-2026) Table 37. Global C-X-C Chemokine Receptor Type 2 Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global C-X-C Chemokine Receptor Type 2 Sales Value Share by Region (2027-2032) Table 39. Global C-X-C Chemokine Receptor Type 2 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global C-X-C Chemokine Receptor Type 2 Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global C-X-C Chemokine Receptor Type 2 Sales Value Market Share by Country (2021-2026) Table 42. Global C-X-C Chemokine Receptor Type 2 Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global C-X-C Chemokine Receptor Type 2 Sales Value Market Share by Country (2027-2032) Table 44. ChemoCentryx Inc Company Information Table 45. ChemoCentryx Inc Business Overview Table 46. ChemoCentryx Inc C-X-C Chemokine Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. ChemoCentryx Inc C-X-C Chemokine Receptor Type 2 Product Portfolio Table 48. ChemoCentryx Inc Recent Development Table 49. Dompe Farmaceutici SpA Company Information Table 50. Dompe Farmaceutici SpA Business Overview Table 51. Dompe Farmaceutici SpA C-X-C Chemokine Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Dompe Farmaceutici SpA C-X-C Chemokine Receptor Type 2 Product Portfolio Table 53. Dompe Farmaceutici SpA Recent Development Table 54. Syntrix Biosystems Inc Company Information Table 55. Syntrix Biosystems Inc Business Overview Table 56. Syntrix Biosystems Inc C-X-C Chemokine Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Syntrix Biosystems Inc C-X-C Chemokine Receptor Type 2 Product Portfolio Table 58. Syntrix Biosystems Inc Recent Development Table 59. AstraZeneca Plc Company Information Table 60. AstraZeneca Plc Business Overview Table 61. AstraZeneca Plc C-X-C Chemokine Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. AstraZeneca Plc C-X-C Chemokine Receptor Type 2 Product Portfolio Table 63. AstraZeneca Plc Recent Development Table 64. GlaxoSmithKline Plc Company Information Table 65. GlaxoSmithKline Plc Business Overview Table 66. GlaxoSmithKline Plc C-X-C Chemokine Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. GlaxoSmithKline Plc C-X-C Chemokine Receptor Type 2 Product Portfolio Table 68. GlaxoSmithKline Plc Recent Development Table 69. Novartis AG Company Information Table 70. Novartis AG Business Overview Table 71. Novartis AG C-X-C Chemokine Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Novartis AG C-X-C Chemokine Receptor Type 2 Product Portfolio Table 73. Novartis AG Recent Development Table 74. Research Programs/Design for This Report Table 75. Authors List of This Report Table 76. Secondary Sources Table 77. Primary Sources List of Figures Figure 1. C-X-C Chemokine Receptor Type 2 Product Image Figure 2. Global C-X-C Chemokine Receptor Type 2 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global C-X-C Chemokine Receptor Type 2 Market Size (2021-2032) & (US$ Million) Figure 4. Global C-X-C Chemokine Receptor Type 2 Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. SX-517 Image Figure 8. PAC-G31P Image Figure 9. DF-2755A Image Figure 10. AZD-5069 Image Figure 11. Others Image Figure 12. Global C-X-C Chemokine Receptor Type 2 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global C-X-C Chemokine Receptor Type 2 Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global C-X-C Chemokine Receptor Type 2 Sales Value Share by Type (2021-2032) Figure 15. Prostate Cancer Image Figure 16. Cornary Artery Disease Image Figure 17. Liver Transplant Rejection Image Figure 18. Pulmonary Inflammation Image Figure 19. Others Image Figure 20. Global C-X-C Chemokine Receptor Type 2 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global C-X-C Chemokine Receptor Type 2 Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global C-X-C Chemokine Receptor Type 2 Sales Value Share by Application (2021-2032) Figure 23. Global C-X-C Chemokine Receptor Type 2 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global C-X-C Chemokine Receptor Type 2 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America C-X-C Chemokine Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 26. North America C-X-C Chemokine Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe C-X-C Chemokine Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 28. Europe C-X-C Chemokine Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific C-X-C Chemokine Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific C-X-C Chemokine Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America C-X-C Chemokine Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 32. South America C-X-C Chemokine Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa C-X-C Chemokine Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa C-X-C Chemokine Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • SX-517
  • PAC-G31P
  • DF-2755A
  • AZD-5069
  • Others
Applications
  • Prostate Cancer
  • Cornary Artery Disease
  • Liver Transplant Rejection
  • Pulmonary Inflammation
  • Others
Companies covered
  • ChemoCentryx Inc
  • Dompe Farmaceutici SpA
  • Syntrix Biosystems Inc
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global C-X-C Chemokine Receptor Type 2 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global C-X-C Chemokine Receptor Type 2 Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 C-X-C Chemokine Receptor Type 2 Market Dynamics
  1. 2.1 C-X-C Chemokine Receptor Type 2 Industry Trends
  2. 2.2 C-X-C Chemokine Receptor Type 2 Industry Drivers
  3. 2.3 C-X-C Chemokine Receptor Type 2 Industry Opportunities and Challenges
  4. 2.4 C-X-C Chemokine Receptor Type 2 Industry Restraints
3 C-X-C Chemokine Receptor Type 2 Market by Company
  1. 3.1 Global C-X-C Chemokine Receptor Type 2 Company Revenue Ranking in 2025
  2. 3.2 Global C-X-C Chemokine Receptor Type 2 Revenue by Company (2021-2026)
  3. 3.3 Global C-X-C Chemokine Receptor Type 2 Company Ranking (2024-2026)
  4. 3.4 Global C-X-C Chemokine Receptor Type 2 Company Manufacturing Base and Headquarters
  5. 3.5 Global C-X-C Chemokine Receptor Type 2 Company Product Type and Application
  6. 3.6 Global C-X-C Chemokine Receptor Type 2 Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global C-X-C Chemokine Receptor Type 2 Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 C-X-C Chemokine Receptor Type 2 Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 C-X-C Chemokine Receptor Type 2 Market by Type
  1. 4.1 C-X-C Chemokine Receptor Type 2 Type Introduction
  2. 4.1.1 SX-517
  3. 4.1.2 PAC-G31P
  4. 4.1.3 DF-2755A
  5. 4.1.4 AZD-5069
  6. 4.1.5 Others
  7. 4.2 Global C-X-C Chemokine Receptor Type 2 Sales Value by Type
  8. 4.2.1 Global C-X-C Chemokine Receptor Type 2 Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global C-X-C Chemokine Receptor Type 2 Sales Value by Type (2021-2032)
  10. 4.2.3 Global C-X-C Chemokine Receptor Type 2 Sales Value Share by Type (2021-2032)
5 C-X-C Chemokine Receptor Type 2 Market by Application
  1. 5.1 C-X-C Chemokine Receptor Type 2 Application Introduction
  2. 5.1.1 Prostate Cancer
  3. 5.1.2 Cornary Artery Disease
  4. 5.1.3 Liver Transplant Rejection
  5. 5.1.4 Pulmonary Inflammation
  6. 5.1.5 Others
  7. 5.2 Global C-X-C Chemokine Receptor Type 2 Sales Value by Application
  8. 5.2.1 Global C-X-C Chemokine Receptor Type 2 Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global C-X-C Chemokine Receptor Type 2 Sales Value by Application (2021-2032)
  10. 5.2.3 Global C-X-C Chemokine Receptor Type 2 Sales Value Share by Application (2021-2032)
6 C-X-C Chemokine Receptor Type 2 Regional Value Analysis
  1. 6.1 Global C-X-C Chemokine Receptor Type 2 Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global C-X-C Chemokine Receptor Type 2 Sales Value by Region (2021-2032)
  3. 6.2.1 Global C-X-C Chemokine Receptor Type 2 Sales Value by Region: 2021-2026
  4. 6.2.2 Global C-X-C Chemokine Receptor Type 2 Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America C-X-C Chemokine Receptor Type 2 Sales Value (2021-2032)
  7. 6.3.2 North America C-X-C Chemokine Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe C-X-C Chemokine Receptor Type 2 Sales Value (2021-2032)
  10. 6.4.2 Europe C-X-C Chemokine Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific C-X-C Chemokine Receptor Type 2 Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific C-X-C Chemokine Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America C-X-C Chemokine Receptor Type 2 Sales Value (2021-2032)
  16. 6.6.2 South America C-X-C Chemokine Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa C-X-C Chemokine Receptor Type 2 Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa C-X-C Chemokine Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
7 C-X-C Chemokine Receptor Type 2 Country-level Value Analysis
  1. 7.1 Global C-X-C Chemokine Receptor Type 2 Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global C-X-C Chemokine Receptor Type 2 Sales Value by Country (2021-2032)
  3. 7.2.1 Global C-X-C Chemokine Receptor Type 2 Sales Value by Country (2021-2026)
  4. 7.2.2 Global C-X-C Chemokine Receptor Type 2 Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt C-X-C Chemokine Receptor Type 2 Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt C-X-C Chemokine Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt C-X-C Chemokine Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ChemoCentryx Inc
  2. 8.1.1 ChemoCentryx Inc Company Information
  3. 8.1.2 ChemoCentryx Inc Business Overview
  4. 8.1.3 ChemoCentryx Inc C-X-C Chemokine Receptor Type 2 Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ChemoCentryx Inc C-X-C Chemokine Receptor Type 2 Product Portfolio
  6. 8.1.5 ChemoCentryx Inc Recent Developments
  7. 8.2 Dompe Farmaceutici SpA
  8. 8.2.1 Dompe Farmaceutici SpA Company Information
  9. 8.2.2 Dompe Farmaceutici SpA Business Overview
  10. 8.2.3 Dompe Farmaceutici SpA C-X-C Chemokine Receptor Type 2 Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Dompe Farmaceutici SpA C-X-C Chemokine Receptor Type 2 Product Portfolio
  12. 8.2.5 Dompe Farmaceutici SpA Recent Developments
  13. 8.3 Syntrix Biosystems Inc
  14. 8.3.1 Syntrix Biosystems Inc Company Information
  15. 8.3.2 Syntrix Biosystems Inc Business Overview
  16. 8.3.3 Syntrix Biosystems Inc C-X-C Chemokine Receptor Type 2 Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Syntrix Biosystems Inc C-X-C Chemokine Receptor Type 2 Product Portfolio
  18. 8.3.5 Syntrix Biosystems Inc Recent Developments
  19. 8.4 AstraZeneca Plc
  20. 8.4.1 AstraZeneca Plc Company Information
  21. 8.4.2 AstraZeneca Plc Business Overview
  22. 8.4.3 AstraZeneca Plc C-X-C Chemokine Receptor Type 2 Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Plc C-X-C Chemokine Receptor Type 2 Product Portfolio
  24. 8.4.5 AstraZeneca Plc Recent Developments
  25. 8.5 GlaxoSmithKline Plc
  26. 8.5.1 GlaxoSmithKline Plc Company Information
  27. 8.5.2 GlaxoSmithKline Plc Business Overview
  28. 8.5.3 GlaxoSmithKline Plc C-X-C Chemokine Receptor Type 2 Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Plc C-X-C Chemokine Receptor Type 2 Product Portfolio
  30. 8.5.5 GlaxoSmithKline Plc Recent Developments
  31. 8.6 Novartis AG
  32. 8.6.1 Novartis AG Company Information
  33. 8.6.2 Novartis AG Business Overview
  34. 8.6.3 Novartis AG C-X-C Chemokine Receptor Type 2 Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis AG C-X-C Chemokine Receptor Type 2 Product Portfolio
  36. 8.6.5 Novartis AG Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst